Dual Function Catheter to Prevent Thrombus and Infection

预防血栓和感染的双功能导管

• 批准号: 8249463
• 负责人: Jennifer Ann Neff
• 金额: $ 98.03万
• 依托单位: ALLVIVO VASCULAR, INC.
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-20 至 2014-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8249463
• 关键词: Achievement; Acute; Address; Agreement; Anti-Bacterial Agents; Antibiotic Resistance; Antibiotics; Bacteria; Behavior; Binding; Blood; Catheters; Chemicals; Chronic; Clinical; Clinical Trials; Contracts; DNA Sequence Rearrangement; Development; Device Approval; Devices; Dimensions; End stage renal failure; Ensure; Exposure to; Goals; Growth; Health Care Costs; Hemodialysis; Infection; Infection Control; Infection prevention; Intravenous; Lead; Length of Stay; Manufacturer Name; Marketing; Mechanics; Medical Device; Methods; Microbial Biofilms; Molecular; Morbidity - disease rate; Patient Care; Patients; Peptides; Performance; Phase; Polyethylene Glycols; Polyurethanes; Positioning Attribute; Preclinical Testing; Prevention; Process; Product Approvals; Production; Program Development; Property; Proteins; Quality of Care; Recording of previous events; Relative (related person); Research; Resistance; Resistance development; Risk; Sales; Small Business Innovation Research Grant; Solutions; Solvents; Source; Sterilization; Stream; Structure; Surface; Surface Properties; Technology; Thrombus; Treatment Cost; Validation; Work; antimicrobial; antimicrobial drug; antimicrobial peptide; bacterial resistance; base; clinically relevant; combat; comparative efficacy; copolymer; cost; design; experience; flexibility; improved; irradiation; killings; manufacturing process; meetings; mortality; novel; patient population; polybutadiene; prevent; process optimization; programs; public health relevance; research clinical testing; success; ultraviolet irradiation

DESCRIPTION (provided by applicant): The objective of this work is to complete development of a novel antibacterial, acute hemodialysis catheter and conduct the preclinical testing required for FDA approval. This product will address 3 major unmet needs for intravenous catheters by: (1) providing dual function coatings that are resistant to both biofilm and thrombus, (2) incorporating antimicrobial technology that will not stimulate the growth of antibiotic resistant bacteria, and (3) improving the duration of antimicrobial activity relative to existing products. The coating is based on a combination of a novel protein resistant block copolymer and an antimicrobial peptide. Coatings will be produced by binding the peptide to surfaces in two modes (via a flexible tether and via entrapment). Recent studies indicate that this is a viable approach based on the peptide's behavior and suggests antimicrobial activity can be maintained when bound to a surface if sufficient solvent accessibility and molecular mobility are preserved. A layer of the antibacterial peptide prepared in this way should be safe, functional, and long-lasting. A key feature of this technology is that it kills bacteria through a multi-tiered mechanism that is fundamentally different from that of clinical antibiotics and is unlikely to cause bacteria to develop resistance. During the proposed period of support, the coating composition and application process will be optimized. Coated catheters will be evaluated for coating efficacy against clinically relevant bacteria strains, durability and mechanical properties to ensure that the coating process developed does not alter the necessary mechanical properties of the catheter. Coating components will be produced under Good Manufacturing Practice (GMPs) and a GMP manufacturing process will be developed and implemented for production of the fully coated and assembled catheter. Preclinical testing required for FDA approval of the coated catheters will also be completed. At the end of this development program, the company will be ready to submit a 510k application and plan to begin post approval clinical testing. The results of this work will have a significant impact on the ability to deliver quality care to both acute and end stage renal disease hemodialysis patients and will decrease their risks of morbidity and mortality due to infections. It will also have a significant impact on the ability to control the rapidly growing cost of treating these patient populations by preventing costly catheter related blood stream infections. PUBLIC HEALTH RELEVANCE: Antibacterial coatings are key to the prevention of medical device related infections, which are a cause of high morbidity and mortality, longer hospital stays, and unnecessary treatment costs. This project aims to develop a new antimicrobial coating technology and apply it to produce an antimicrobial hemodialysis catheter that will prevent biofilms without compromising the efficacy of the limited arsenal of clinical antibiotics. This technology is expected to substantially decrease morbidity and mortality for acute and chronic hemodialysis patients as well as help contain their treatment cost by preventing infections. This research program will potentially yield a solution to the fundamental problem of biofilm formation on medical devices and will be an important step toward responsible infection control.

描述(由申请人提供)：这项工作的目标是完成一种新型抗菌急性血液透析导管的开发，并进行FDA批准所需的临床前测试。该产品将通过以下方式解决静脉导管的三大未得到满足的需求：(1)提供同时抵抗生物膜和血栓的双功能涂层，(2)采用不会刺激抗生素耐药细菌生长的抗菌技术，以及(3)与现有产品相比，延长抗菌活性的持续时间。该涂层是基于一种新型的抗蛋白质嵌段共聚物和一种抗菌肽的组合。涂层将通过两种方式将多肽结合到表面上(通过柔性系绳和通过包埋)。最近的研究表明，基于多肽的行为，这是一种可行的方法，并表明如果保持足够的溶剂可及性和分子流动性，当结合到表面时可以保持抗菌活性。用这种方法制备的一层抗菌肽应该是安全的、功能性的和持久的。这项技术的一个关键特点是，它通过一种与临床抗生素根本不同的多层机制杀死细菌，不太可能导致细菌产生抗药性。在拟议的支撑期内，将优化涂层成分和涂装工艺。将评估涂层导管对临床相关细菌菌株的涂层效果、耐用性和机械性能，以确保所开发的涂层工艺不会改变导管的必要机械性能。涂层组件将按照良好制造规范(GMPs)生产，GMP制造流程将被开发和实施，以生产完全涂层和组装的导管。FDA批准涂层导管所需的临床前测试也将完成。在这一开发计划结束时，该公司将准备提交510k申请，并计划开始批准后的临床测试。这项工作的结果将对向急性和终末期肾病血液透析患者提供高质量护理的能力产生重大影响，并将降低他们因感染而发病和死亡的风险。它还将对通过预防昂贵的导管相关血流感染来控制这些患者群体迅速增长的治疗成本的能力产生重大影响。 公共卫生相关性：抗菌涂层是预防医疗器械相关感染的关键，这些感染会导致高发病率和死亡率、更长的住院时间和不必要的治疗成本。该项目旨在开发一种新的抗菌涂层技术，并将其应用于生产抗菌血液透析导管，该导管将在不影响有限的临床抗生素药库的效果的情况下防止生物被膜。这项技术预计将大大降低急性和慢性血液透析患者的发病率和死亡率，并通过预防感染帮助控制他们的治疗成本。这项研究计划可能会解决医疗器械上生物被膜形成的根本问题，并将是朝着负责任的感染控制迈出的重要一步。